Heparin-induced thrombocytopenia is a life-threatening immune-mediated complication of unfractionated heparin therapy. Fondaparinux is a therapeutic alternative, but it has limited evidence for its use in patients on extracorporeal membrane oxygenation (ECMO). We present a series of three adult patients with COVID-19 on ECMO who were diagnosed with heparin-induced thrombocytopenia after 7-12 days of unfractionated heparin treatment and were switched to fondaparinux. Fondaparinux was initiated with an intravenous loading dose of 5 mg, followed by a dose of 2.5 mg subcutaneously every 8-12 h. Dosage was adjusted according to daily measured anti-Xa concentration with a target range of 0.4-0.7 mg/L. The total duration of treatment with fondaparinux and ECMO ranged from 13 to 26 days. One major bleeding episode unrelated to fondaparinux therapy was observed, and the transfusions requirement was also low in all patients. The ECMO circuit was changed once in each patient. This series provides a deep insight into the use of fondaparinux over an extended period of time in patients on ECMO. Based on the presented data, fondaparinux can be considered a reasonable and affordable anticoagulant in patients without a high risk of bleeding.

Department of Anesthesiology and Intensive Care Faculty of Medicine Masaryk University St Anne's University Hospital Brno Brno Czechia

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czechia

International Clinical Research Center St Anne's University Hospital Brno Brno Czechia

Zobrazit více v PubMed

McMichael ABV, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. (2022) 68:303–10. 10.1097/MAT.0000000000001652 PubMed DOI

Mansour A, Flecher E, Schmidt M, Rozec B, Gouin-Thibault I, Esvan M, et al. . Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. Intensive Care Med. (2022) 48:1039–52. 10.1007/s00134-022-06794-y PubMed DOI

Jiritano F, Serraino GF, Ten Cate H, Fina D, Matteucci M, Mastroroberto P, et al. . Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis. Intensive Care Med. (2020) 46:1154–69. 10.1007/s00134-020-06031-4 PubMed DOI PMC

Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kelton JG, et al. . Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost. (2021) 19:1342–7. 10.1111/jth.15283 PubMed DOI PMC

Uaprasert N, Tangcheewinsirikul N, Rojnuckarin P, Patell R, Zwicker JI, Chiasakul T. Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. Blood Adv. (2021) 5:4521–34. 10.1182/bloodadvances.2021005314 PubMed DOI PMC

East JM, Cserti-Gazdewich CM, Granton JT. Heparin-induced thrombocytopenia in the critically ill patient. Chest. (2018) 154:678–90. 10.1016/j.chest.2017.11.039 PubMed DOI

Patell R, Khan AM, Bogue T, Merrill M, Koshy A, Bindal P, et al. . Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol. (2020) 95:E295–6. 10.1002/ajh.25935 PubMed DOI PMC

EMA. Arixtra. European Medicines Agency (2018). Available online at: https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra (accessed August 03, 2022).

Loforte A, Montalto A, Ranocchi F, Della Monica PL, Casali G, Lappa A, et al. . Peripheral extracorporeal membrane oxygenation system as salvage treatment of patients with refractory cardiogenic shock: preliminary outcome evaluation. Artif Organs. (2012) 36:E53–61. 10.1111/j.1525-1594.2011.01423.x PubMed DOI

Parlar AI, Sayar U, Cevirme D, Yuruk MA, Mataraci I. Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery. Int J Artif Organs. (2014) 37:344–7. 10.5301/ijao.5000302 PubMed DOI

Degani A, Milanesi E, Rossini B, Ricccardi MC, Pellegrini C, Doronzo F, et al. . Case report: use of subcutaneous Fondaparinux in a COVID 19 patient with heparin-induced thrombocytopenia during venous-venous ECMO. Perfusion. (2021) 36(1 suppl):46–7.

Keam SJ, Goa KL. Fondaparinux sodium. Drugs. (2002) 62:1673–87. 10.2165/00003495-200262110-00007 PubMed DOI

Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, et al. . The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. (2002) 41(Suppl. 2):1–9. 10.2165/00003088-200241002-00001 PubMed DOI

PubChem. Pubchem Fondaparinux. (2022). Available online at: https://pubchem.ncbi.nlm.nih.gov/compound/5282448 (accessed August 02, 2022).

Ha MA, Sieg AC. Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy. (2017) 37:221–35. 10.1002/phar.1882 PubMed DOI

Johnson PN, Benefield EC, Bui PYN, Gausman JN, Marlar RA, Gessouroun MR. Fondaparinux monitoring: need for a local fondaparinux-calibrated anti–f actor Xa assay. J Pediatr Pharmacol Ther. (2013) 18:318–9. 10.5863/1551-6776-18.4.318 PubMed DOI PMC

Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. (2016) 41:15–31. 10.1007/s11239-015-1314-3 PubMed DOI PMC

DailyMed. DailyMed - ARIXTRA- Fondaparinux Sodium Injection, Solution. (2012). Available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec235119-cb58-4939-942c-11d3923d289f (accessed August 03, 2022).

Wahby KA, Riley LK, Tennenberg SD. Assessment of an extended interval fondaparinux dosing regimen for venous thromboembolism prophylaxis in critically ill patients with severe renal dysfunction using antifactor Xa levels. Pharmacotherapy. (2017) 37:1241–8. 10.1002/phar.2014 PubMed DOI

Knopp A, Ammar A, Rouse G, Tran L, Ammar M. 1222: safety and efficacy of fondaparinux in renal insufficiency utilizing anti-Xa monitoring. Crit Care Med. (2022) 50:611. 10.1097/01.ccm.0000811212.70128.f4 DOI

Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. (2016) 41:165–86. 10.1007/s11239-015-1315-2 PubMed DOI PMC

Schulman S Kearon C Subcommittee Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. (2005) 3:692–4. 10.1111/j.1538-7836.2005.01204.x PubMed DOI

Appelt H, Philipp A, Mueller T, Foltan M, Lubnow M, Lunz D, et al. . Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)-comparison of VA- versus VV ECMO. PLoS ONE. (2020) 15:e0227793. 10.1371/journal.pone.0227793 PubMed DOI PMC

Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. . American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. (2018) 2:3360–92. 10.1182/bloodadvances.2018024489 PubMed DOI PMC

Li D, Sun M, Zhang J, Zhang C, Deng L, Jiang H. Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis. Thromb Res. (2022) 210:53–62. 10.1016/j.thromres.2021.12.024 PubMed DOI

Geli J, Capoccia M, Maybauer DM, Maybauer MO. Argatroban anticoagulation for adult extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med. (2022) 37:459–71. 10.1177/0885066621993739 PubMed DOI

Campbell CT, Diaz L, Kelly B. Description of bivalirudin use for anticoagulation in pediatric patients on mechanical circulatory support. Ann Pharmacother. (2021) 55:59–64. 10.1177/1060028020937819 PubMed DOI

Aljabri A, Huckleberry Y, Karnes J, Gharaibeh M, Kutbi HI, Raz Y, et al. . Cost-effectiveness of anticoagulants for the management of suspected heparin-induced thrombocytopenia in the US. Blood. (2016) 128:3043–51. 10.1182/blood-2016-07-728030 PubMed DOI PMC

Update on Anticoagulation Strategies in Patients with ECMO-A Narrative Review